{
    "id": "3f726b10-ef7b-47d6-96c9-e1a7ee5461d9",
    "code": {
        "code": "34391-3",
        "codeSystem": "2.16.840.1.113883.6.1",
        "displayName": "HUMAN PRESCRIPTION DRUG LABEL"
    },
    "name": "Ciprofloxacin Otic",
    "organization": "Genus Lifesciences",
    "effectiveTime": "20250415",
    "ingredients": [
        {
            "name": "Ciprofloxacin",
            "code": "5E8K9I0O4U"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "LACTIC ACID, UNSPECIFIED FORM",
            "code": "33X04XA5AT"
        }
    ],
    "indications": "1 usage ciprofloxacin otic solution, 0.2% quinolone antimicrobial indicated treatment acute otitis externa due susceptible isolates pseudomonas aeruginosa staphylococcus aureus . ciprofloxacin otic solution, 0.2% quinolone antimicrobial indicated treatment acute otitis externa due susceptible isolates pseudomonas aeruginosa staphylococcus aureus . ( 1 )",
    "contraindications": "4 ciprofloxacin otic solution, 0.2% contraindicated persons history hypersensitivity ciprofloxacin. history hypersensitivity ciprofloxacin. ( 3 )",
    "warningsAndPrecautions": "5 ciprofloxacin otic solution, 0.2% otic only. ( 5.1 ) hypersensitivity: discontinue first appearance skin rash sign hypersensitivity. ( 5.2 ) ciprofloxacin otic solution, 0.2% may result overgrowth nonsusceptible organisms. ( 5.3 ) 5.1 otic ciprofloxacin otic solution, 0.2% otic only. used injection, inhalation topical ophthalmic use. 5.2 hypersensitivity ciprofloxacin otic solution, 0.2% discontinued first appearance skin rash sign hypersensitivity. 5.3 growth rsistant organisms prolonged anti-infectives, ciprofloxacin otic solution, 0.2% may result overgrowth nonsusceptible organisms, including yeast fungi. super-infection occurs, discontinue institute alternative therapy. 5.4 lack response infection improved one week therapy, cultures may help guide treatment.",
    "adverseReactions": "6 conducted widely varying conditions, reaction rates observed cannot directly compared rates another may reflect rates observed practice. randomized, active-controlled trial, approximately 300 patients signs symptoms otitis externa treated ciprofloxacin otic solution, 0.2% . frequently reported application site pain, ear pruritus, fungal ear superinfection, headache, reported approximately 2-3% patients. common reported 2-3% patients treated ciprofloxacin otic solution, 0.2% application site pain, ear pruritus, fungal ear superinfection headache. ( 6 ) report suspected reactions, contact allucent 1-866-511-6754 fda 1-800-fda-1088 www.fda.gov/medwatch . ( 6 )",
    "indications_original": "1 INDICATIONS AND USAGE Ciprofloxacin otic solution, 0.2% is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus . Ciprofloxacin otic solution, 0.2% is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus . ( 1 )",
    "contraindications_original": "4 CONTRAINDICATIONS Ciprofloxacin otic solution, 0.2% is contraindicated in persons with a history of hypersensitivity to ciprofloxacin. History of hypersensitivity to ciprofloxacin. ( 3 )",
    "warningsAndPrecautions_original": "5 WARNINGS AND PRECAUTIONS Ciprofloxacin otic solution, 0.2% is for otic use only. ( 5.1 ) Hypersensitivity: discontinue at the first appearance of a skin rash or any other sign of hypersensitivity. ( 5.2 ) Use of ciprofloxacin otic solution, 0.2% may result in overgrowth of nonsusceptible organisms. ( 5.3 ) 5.1  Otic Use Only Ciprofloxacin otic solution, 0.2% is for otic use only. It should not be used for injection, for inhalation or for topical ophthalmic use. 5.2  Hypersensitivity Ciprofloxacin otic solution, 0.2% should be discontinued at the first appearance of a skin rash or any other sign of hypersensitivity. 5.3  Growth of Rsistant Organisms with Prolonged Use As with other anti-infectives, use of ciprofloxacin otic solution, 0.2% may result in overgrowth of nonsusceptible organisms, including yeast and fungi. If super-infection occurs, discontinue use and institute alternative therapy. 5.4  Lack of Clinical Response If the infection is not improved after one week of therapy, cultures may help guide further treatment.",
    "adverseReactions_original": "6 ADVERSE REACTIONS Because clinical studies are conducted under widely varying conditions, adverse drug reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice. In a randomized, active-controlled clinical trial, approximately 300 patients with clinical signs and symptoms of otitis externa were treated with ciprofloxacin otic solution, 0.2%. The most frequently reported adverse reactions were application site pain, ear pruritus, fungal ear superinfection, and headache, each reported in approximately 2-3% of patients. The most common adverse reactions reported in 2-3% of patients treated with ciprofloxacin otic solution, 0.2% were application site pain, ear pruritus, fungal ear superinfection and headache. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Allucent at 1-866-511-6754 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . ( 6 )"
}